Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
JCPSP-Journal of the College of Physicians and Surgeons Pakistan. 1996; 6 (1): 9-11
em Inglês | IMEMR | ID: emr-95926

RESUMO

A prospective study was carried out on all HBsAg positive patients [n=43] with fulminant hepatic failure admitted between March 1994 and November 1994 to the Department of Medicine, Nishtar Medical College, Multan, to assess the prevalence of delta markers. Of these, 19 [44.2%] were positive for hepatitis D virus [HDV] markers and 24 [55.8%] were negative. The frequency of severe encephalopathy [grade IV and V] was higher among anti-HD positive patients [79%] as compared to anti-HD negative patients [45.8%], and the difference was significant [p<0.5]. The mortality was also higher in the anti-HD positive group [57.9%] as opposed to anti-HD negative group [37.5%]. The fact that HBV and HDV infections are endemic in this region and that HDV markers are present in a significant number of HBsAg positive patients, emphasizes the need for development of effective strategies for prophylaxis against both infections


Assuntos
Hepatite D/fisiopatologia , Vírus Delta da Hepatite/patogenicidade , Antígenos de Superfície da Hepatite B/análise , Falência Hepática/etiologia , Estudos Prospectivos/métodos
2.
Bol. Hosp. San Juan de Dios ; 41(5): 308-18, sept.-oct. 1994. tab
Artigo em Espanhol | LILACS | ID: lil-148329

RESUMO

El conocimiento de las hepatitis se remonta por lo menos al siglo VIII, pero éste ha avanzado vertiginosamente en los últimos 30 años gracias a factores como la aplicación de técnicas de inmunoquímica, microscopía electrónica, estudios epidemiológicos tanto clínicos como experimentales, técnicas de ingeniería genética, etc. Este trabajo revisa aspectos históricos de estas afecciones, las lateraciones histológicas hepáticas y manifestaciones clínicas que desencadenan. También describe las características principales de los virus A, B, C y E, la respuesta inmune que produce cada uno de ellos, su forma de infectar y la evolución, complicaciones y posibilidades de prevención de la enfermedad que desencadenan. Se comentan los resultados de los tratamientos con antivirales e interferón para las infecciones crónicas por virus B y C


Assuntos
Humanos , Hepatite Viral Humana/fisiopatologia , Hepatite/história , Antivirais/administração & dosagem , Hepacivirus/patogenicidade , Hepatite A/microbiologia , Hepatite A/fisiopatologia , Vírus da Hepatite B/patogenicidade , Hepatite B/tratamento farmacológico , Hepatite B/microbiologia , Hepatite B/fisiopatologia , Vírus Delta da Hepatite/patogenicidade , Hepatite D/microbiologia , Hepatite D/fisiopatologia , Vírus da Hepatite E/patogenicidade , Hepatite E/microbiologia , Hepatite E/fisiopatologia , Hepatovirus/patogenicidade
3.
Acta méd. colomb ; 17(3): 180-5, mayo-jun. 1992. tab
Artigo em Espanhol | LILACS | ID: lil-183236

RESUMO

The etiologic agent of this severe form of hepatitis was identified by Rizzetto et al in Italy in 1977. The Delta virus resembles satellite viruses of plants which can not replicate without another specific virus. In this particular case hepatitis B virus is the helper agent. Clinically this form of hepatitis is characterized by two presentations: coinfeccion, which means simultaneous infection of a host with hepatitis B virus and hepatitis D virus. This variety of hepatitis can present with two distinct peaks of transaminases and usually resolves completely in most of the cases, however 0-4 percent can evolve to chronic hepatitis and 25 percent of the cases of fulminant hepatitis are due to this viral association. The diagnosis can be established demonstrating anti-HDV IgM or HDV-RNA or HDV antigen in the serum. In essence coinfection makers acute hepatic failure more common and the mortality is significantly higher than hepatitis B infections by itself. The second type of clinical presentation is superinfection, which means infection with the Delta virus of a patient previously infected with the hepatitis B virus (healthy carrier). Initially the patient develop a typical acute viral hepatitis in 50-70 percent of the cases, and 30-50 percent can have asymptomatic infection. The real problem with this presentation is that 20-90 percent of the cases evolved to chronicity: chronic active hepatitis and cirrhosis. The diagnosis can be made demonstrating anti-HDB IgM and anti-HDV IfG, although this last one is usually transitory. A liver biopsy can show HDV RNA or HDV antigen using special immunostainings...


Assuntos
Humanos , Vírus Delta da Hepatite/crescimento & desenvolvimento , Vírus Delta da Hepatite/imunologia , Vírus Delta da Hepatite/isolamento & purificação , Vírus Delta da Hepatite/patogenicidade , Vírus Delta da Hepatite/fisiologia , Hepatite D/complicações , Hepatite D/diagnóstico , Hepatite D/tratamento farmacológico , Hepatite D/epidemiologia , Hepatite D/etiologia , Hepatite D/imunologia , Hepatite D/fisiopatologia , Hepatite D/terapia
5.
In. Restrepo G., Jorge Emilio; Guzman V., Jose Miguel; Botero A., Rafael Claudino; Velez A., Hernan; Ruiz P., Oscar. Gastroenterologia hematologia nutricion. Medellin, Corporacion para Investigaciones Biologicas, 1990. p.430-52, ilus, tab.
Monografia em Espanhol | LILACS | ID: lil-133891
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA